{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 25/80', '3.', 'CLINICAL STUDY OBJECTIVES', '3.1.', 'PRIMARY OBJECTIVE', '-', 'To evaluate the efficacy of GLPG1690 as evaluated by mRSS compared to placebo over', '24 weeks for the treatment of subjects with systemic sclerosis', '3.2.', 'SECONDARY OBJECTIVE', '-', 'To evaluate the safety and tolerability of GLPG1690 compared to placebo over 24 weeks', 'in the treatment of subjects with systemic sclerosis', '3.3.', 'OTHER OBJECTIVES', '4.', 'INVESTIGATIONAL PLAN', '4.1.', 'OVERALL CLINICAL STUDY DESIGN', 'This is a randomized, double-blind, parallel-group, placebo-controlled, multi-center, Phase 2a', 'study designed to evaluate the efficacy, safety, and tolerability of a 600 mg q.d. dose of orally', 'administered GLPG1690 over 24 weeks in approximately 30 adult subjects with a confirmed', 'diagnosis of systemic sclerosis.', 'At Day 1/Visit 2 (baseline), subjects will be randomized in a 2:1 ratio to GLPG1690', '600 mg q.d. taken as three film-coated tablets of 200 mg, or matching placebo q.d. administered', 'for 24 weeks in addition to background treatment as defined in Section 4.5.3.2, \"Prior and', 'Concomitant medications\".', 'A schematic diagram of the clinical study design, procedures, and stages is provided in Figure 1.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 26/80', 'Screening', 'Dosing Period', 'Follow-up', '(Max. 28 Days)', '(24 Weeks)', '(12 Weeks)', 'V2', 'V3', 'V4', 'V5', 'V6', 'V7', 'V8', 'V9', 'FU1', 'FU2', 'D1', 'W2', 'W4', 'W8', 'W12*', 'W16', 'W20*', 'W24', 'W28', 'W36', 'V1', 'Systemic Sclerosis', 'Diffuse Cutaneous', 'GLPG1690 600 mg q.d.', 'Subjects', 'Matching Placebo q.d.', 'Figure 1:', 'Schematic Study Overview', 'D=Day, FU=Follow-up, V=Visit, W=Week', '* This will be a phone call to assess safety (no clinical study center visit).', 'For the in- and exclusion criteria please refer to Section 4.5.1, \"Inclusion Criteria\" and', 'Section 4.5.2, \"Exclusion Criteria\".', 'The subjects will visit the clinical study center at screening/Visit 1 (Day -28 to Day -1),', 'Day 1/Visit 2 (baseline), Day 15 (Week 2/Visit 3), Day 29 (Week 4/Visit 4), Day 57', '(Week 8/Visit 5), Day 113 (Week 16/Visit 7), Day 169 (Week 24/Visit 9), and, if applicable,', 'the ED visit. At Weeks 12 (Visit 6) and 20 (Visit 8), a phone call will be made to assess safety.', 'In addition, a follow-up visit will be planned 4 weeks after the last administration of IMP', '(Day 197 [Week 28]) (i.e. Follow-up Visit 1) and a second follow-up visit will be planned', '12 weeks after the last administration of IMP (Day 253 [Week 36]) (i.e. Follow-up Visit 2).', 'Additional unscheduled visits are allowed for any safety assessments if clinically indicated (see', 'Section 6.2).', 'For any subjects who, due to any COVID-19-related reason, cannot perform Visit 9 (Week 24),', 'within the time window of +4 days, the window for the visit may be increased to 28 days.', 'Each subject will be in the study for up to approximately 40 weeks (up to 4 weeks of screening,', '24 weeks of treatment, and 12 weeks of follow-up). Covid-19 mitigation measures may', 'increase the time in the study up to approximately 44 weeks.', 'For detailed info regarding dosage form, packaging, and labeling of the IMP, please refer to', 'Section 5.2, \"Dosage and Administration\" and Section 5.3, \"Packaging, Labeling, and', 'Distribution\".', 'The end of the study (EoS) is reached when the last visit of the last subject is performed.', 'Open-label Extension', 'Subjects who completed the Week 24 visit will be offered treatment with GLPG1690 in an', 'optional open-label extension, provided regulatory and Independent Ethics Committee', '(IEC)/Institutional Review Board (IRB) approvals for such an extension is granted. In this case,', 'the follow-up visits are not performed for these subjects. This extension is described in a', 'separate protocol, Study GLPG1690-CL-206.', 'For the rollover of a subject into the GLPG1690-CL-206 study, a complete rollover visit, at', 'Visit 9 of this study (GLPG1690-CL-204), is required.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}